NZ231447A

NZ231447A - Two component absorption enhancing system for antibacterial composition

Info

Publication number: NZ231447A
Application number: NZ231447A
Authority: NZ
Inventors: Maria Oksana Bachynsky; Martin Howard Infeld; Navnit Shah; Joel Unowsky
Original assignee: Hoffmann La Roche
Priority date: 1988-11-22
Filing date: 1989-11-20
Publication date: 1992-09-25
Also published as: AU4538489A; HU205713B; PH26390A; IE893718L; ATE94765T1; DK585889D0; EP0370481A2; ZA898331B; JPH02180837A; IL92357A0; CA2003340A1; HU896123D0; KR900007412A; HUT52374A; IL92357A; EP0370481A3; YU221889A; AU625276B2; DK585889A; EP0370481B1

Abstract

Pharmaceutical product containing (a) a compound with antibacterial activity, and (b) an effective amount of an absorption-promoting 2-component system which contains as first component (b 1) an ether composed of a C6-C18-alcohol and polyoxyethylene glycol and as second component either (b 2-1) a polyoxyethylene glycol C6-C18-carboxylic acid glyceride ester, or (b 2-2) a C6-C18-carboxylic acid or a pharmaceutically utilisable salt thereof, or (b 2-3) an ester composed of two or more C6-C18-carboxylic acids, glycerol and a polyoxyethylene glycol.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £31447 No.: Date: Priority Ds*e{s):.-sl&'.VY.S?>. CQ»sr>!«fp Specific....; r: ..^-5s:.>.V.S53..< C'^ss* \>J- | P'jfcSisstK^n Dr.!<s: 3SL5LS£]?..$$Z. j P.O. Join'^a5, %c: 0?.fr£r? 231 447 ? *r^r-c- >» it B < /ft a •jfiS * * -- . Jt Sst%0 fiat z U.J it. NEW ZEALAND PATENTS ACT, 1953 D COMPLETE SPECIFICATION PHARMACEUTICAL COMPOSITIONS 3 K/We, F. HOFFMANN-LA ROCHE AG 124-184 Grenzacherstrasse, CH-4002 Basle, Switzerland, a Swiss Company hereby declare the invention for which ic/ we pray that a patent may be granted to ?jx9;/us, and the method by which it is to be performed, to be particularly described in and by the following statement: - - 1 - (followed by page la) 231447 /q- 5 The present invention relates to pharmaceutical compositions comprising (a) an antibacterial compound and (b) an absorption enhancing amount of a two-component absorption enhancing system made up of a first component which is (1) an ether of a C, to C._ alcohol and a D 18 polyoxyethylene glycol (PEG) having an average molecular weight of from 400 to 6 00 and a second component selected from among (2)(i) a polyoxyethylene glycol - Cc to C, a O 18 carboxylic acid glyceride ester, (2)(ii) a C, to C__ 6 18 carboxylic acid or pharmaceutically acceptable salt thereof, and (2)(iii) an ester of two or more C, to C._ O 18 15 carboxylic acids, glycerol and a polyoxyethylene glycol. Optionally, a pharmaceutically inert carrier can also be included. The term "polyoxyethylene glycol-C to Cn 6 18 2Q carboxylic acid glyceride ester" as used in connection with this invention refers to those reaction products derived from the co-reaction of polyoxyethylene glycol (or polymerizable precursor thereof, such as ethylene oxide) with a C -C.. carboxylic acid and glycerol or with a b 18 25 C6~ci8 cacb°xylic acid glyceride or glycerides. Resulting from such reactions are, typically, mixtures of a polyoxyethylene glycol-Cg to Clg carboxylic acid glyceride ester (e.g., PEG-glycerol-caprate, PEG-glycerol-caprylate or PEG-glycerol-caprylate/caprate), a 30 polyoxyethylene glycol-Cg to Clg carboxylic acid ester (e.g., PEG-caprate, PEG-caprylate or PEG-caprylate/caprate). and a glyceryl-Cg to C^g carboxylic acid ester (e.g., glyceryl mono-, di- or tricaprylate, glyceryl mono-, di- or tricaprate or glyceryl mono-, di- or tricaprylate/_caprate), r 35 * r 1 231447 - 2 - as the principal components. It has been found that the above-identified absorption enhancing system functions to increase the extent of 5 absorption of antibacterial compounds through mucosal tissue and into the bloodstream. This invention thus promotes the absorption and. concomitantly, the bioavailability of antibacterial compounds which, when administered without the absorption enhancer by means other than parenteral, are only 10 poorly absorbed or not absorbed to any appreciable degree. The preparation and use of a greater variety of dosage forms for such compounds are thus enabled. The pharmaceutical compositions of the present invention also promote the greater absorption and bioavailability of antibacterial 15 compounds which are otherwise only moderately absorbed through mucosal tissue, thus enhancing the effectiveness of such therapeutic compounds also. This invention encompasses the aforementioned 20 pharmaceutical composition for administration in virtually any dosage form suitable for oral or rectal administration. Embraced within its scope are oral and rectal types of 'w! pharmaceutical preparations containing effective amounts of an antibacterial compound and an absorption enhancing system 25 in accordance with the present description, with or without an inert carrier and pharmaceutically acceptable adjuvants. K>wm) The terms "antibacterial" and "antibiotic" are used interchangeably throughout this disclosure to refer to 30 bactericidal or bacteriostatic compounds which have been metabolically derived from a microorganism, synthetically prepared by chemical means, or prepared by a combination of microbial and chemical procedures (semi-synthetic). 35 Contemplated for utilization in the practice of this invention is virtually any antibiotic substance which is useful for combatting a bacterial infection in a host. - 3 - 2314 47 \ J including those antibiotics which are only moderately absorbed upon non-injected or non-infused administration. However, this invention finds its greatest usefulness when employed to enhance the absorption and bioavailability of antibiotics which, for the most part, can be effectively administered only by injection or infusion due to non- or poor absorbability via other routes of administration. Among the most preferred antibacterial compounds 10 suitable for use as the therapeutic substance in the practice of this invention are beta-lactam antibiotics, particularly compounds having a beta-lactam ring as the central structure, that is, the structure 15 t 20 25 which can be substituted at various positions on the ring and/or fused with other ring systems which themselves can be substituted or unsubstituted. Exemplary of such beta-lactam antibiotics are penicillins, cephalosporins, penems, carbapenems and monocyclic beta-lactams. Especially preferred beta-lactam antibiotics for use in this invention are compounds of the formula 30 *3v 35 .Ri 231447 - 4 - 10 in which R1 is hydrogen or optionally substituted alkyl. R2 is S03~M+ where M+ is a proton or cation, R^ acylamino group or hydroxyalkyl. or R.^ and R2 is an together with the beta-lactam (azetidinone) ring to which they are bonded represent R3v in which X is -S-, -O, -SO-. -SOp -CHj or -CH(CH3) and Y is group 25 30 in which is a substituted thio group such as ethylthio. -sch2CH2NH2. NH It o w -SCH2CH2NHCH. -SCH2CH2OCNH2, -S 35 CONMe2 7 ^ S i v> ^ \ - c ' /■ ■ C , vr.'\ 25 - 5 - 231447 or an optionally substituted lower alkyl group such as aminomethyl, acylaminomethyl, o w or a substituted oxy group such as carbamoyloxy (-OCNH2), the carbon atom which carries the -COOE group is bonded to the nitrogen atom of the beta-lactam ring, Z is hydrogen, halogen, alkoxy or CH2T. with T denoting hydrogen, alkyl 10 -C0-0-, pyridinium, carboxamidopyridinium, aminopyridinium, carbamoyloxy, azido, cyano, hydroxyl, the group -S-phenyl which can be substituted or the group -S-het wherein "het" is an optionally substituted 5- or 6-membered heterocyclic ring, and E is hydrogen, a pharmaceutically acceptable ester 15 group or a salt-forming cation. Examples of the 5- or 6-membered heterocyclic rings encompassed within "het" above are the following: 20 N N N N N N // w -o«. -<> xn/N I I CHa CH2-CH2-N(CH3)2 N N N N CH3v ,0 -4 \ -J \ ySv s N I CH2CO2H N O 35 Especially preferred beta-lactam antibiotics and their pharmaceutically acceptable salts, esters and hydrates include ceftriaxone, a cephalosporin described in U.S. - 6 - 231447 Patent No. 4,327,210 (Montavon et al.); carumonam, a monocyclic beta-lactam described in European Patent No. EP 73061; piperacillin, a penicillin described in U.S. Patent No. 4,112,090; cefamandole, a cephalosporin described in 5 U.S. Patent No. 3,641,021; mezlocillin, a penicillin described in U.S. Patent No. 3,974,142; and cefazolin, a cephalosporin described in U.S. Patent No. 3,516,997, the disclosures of all of which are incorporated herein by reference. Further included are cefoxitin, cefmetazole, 10 cefotetan, moxalactam, cefuroxime, ceforamide, cefoperazone. ceftizoxime, cefotaxime, cefmenoxime. ceftazidime, cefsulodin, cefazolin, cephalexin, azlocillin, penicillin G, temocillin, sulbenicillin, ticarcillin, mecillinam, amoxicillin, methicillin, carbenicillin, thienamycin, 15 N-formimidoy1thienomycin, sulbactam and azthreonam. Another preferred beta-lactam antibiotic for use in this invention is the compound, (E)-2-(Isobutoxy carbonyl) -2-pentenyl(6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl) 20 -2-(methoxyimino)acetamidoJ-3-(azidomethyl)-8-oxo-5-thia -l-azabicyclo[4.2.0]oct-2-ene-2-carboxylate which is described in European Patent Publication A2-0318767. Also included within the scope of this invention are 25 antibiotics other than the beta-lactams, for example, vancomycin and gentamicin, the absorption and bioavailability of which are improved by use with the described absorption enhancing systems. 30 Absorption enhancing system component (b)(1) is the product of an ether ification reaction between an alcohol, specifically, an acyclic Cr to C., Q straight or branched 6 lo chain alkanol and a polyoxyethylene glycol (PEG) having an average molecular weight of from 400 to 6 00. Examples of alcohols suitable for the preparation of component (b)(1) include n-hexyl, n-heptyl. n-octyl, n-decyl, n-dodecyl ^ ' o (lauryl), n-tetradecyl (myristyl), n-hexadecyl (cetyl^.. V. -» ' c ! \0 . \ <> 23!447 - 7 - n-octadecyl, and so forth. Lauryl alcohol is preferred. The polyoxyethylene glycol is a medium to high molecular weight material which has a number 5 average molecular weight in the range from 400 to 600. Component (b)(1) can be prepared by known procedures. 10 Especially favored for use as component (b)(1) is the material known as Laureth-12 (CTFA designation). A suitable commercially available material is MACOL LA-12, manufactured by Mazer Chemicals Company, Gurnee, Illinois. 15 Absorption enhancing system component (b)(2)(i)# may be the product of an esterification reaction between a polyoxyethylene glycol, glycerol and one or more straight or branched chain C, to C._ carboxylic acids, preferably a 6 lo monofunctional acid or acids. Alternatively, component 20 (b)(2)(i) may be prepared by oligomerizing or polymerizing ethylene oxide in the presence of an ester of glycerol and one or more of such C, to CnD carboxylic acids (glyceride o io esters). Still another route, and the preferred one, is by co-reacting the glyceride ester or esters with a fully 25 pre-formed polyoxyethylene glycol under conditions sufficient to achieve alcoholysis. According to a particular preferred procedure, involving alcoholysis, a reaction vessel is charged with 30 stoichiometric quantities of a glyceryl-fatty acid ester or esters and a polyethylene glycol. The vessel is closed and heated at atmospheric pressure to 200°C, with continuous stirring commenced at 70°C, for a period of 12 to 24 hours or until the reaction is completed. The vessel is allowed 35 to cool and the reaction product is then separated reaction mixture by filtration. ^ ' / - 8 - 231447 Examples of C, to C. carboxylic acids, saturated or 6 18 unsaturated, which are useful for the preparation of absorption enhancing system component (b)(2)(i) are caproic, caprylic, capric, lauric, myristic, oleic, palmitic and stearic. Especially preferred for this invention are capric and caprylic acids, individually or together. The polyoxyethylene glycol (PEG) used in the formation of absorption enhancing system component (b)(2)(i) is, typically, a medium to high molecular weight material, preferably having a number average molecular weight in the range from about 200 to about 1500, and more preferably from about 300 to about 600. A material which is suitable for use as absorption enhancing system component (b)(2)(i) will most preferably have the following characteristics: Organoleptic Properties: Appearance: Odor: Color: clear oily liquid faint pale yellow to yellow Physical and Chemical Properties: Acid Value: Sulfated ash: Saponification index: Iodine index: Moisture content: Free glycerin content: Monoglyceride content: 20 Density (d ): 20 Refractive index (n^ ): 0.2 - 0.6 less than 0.05% 85 - 105 less than 2 less than 0.05% approx. 2% approx. 6 to 8% 1.062 - 1.068 g/cc 1.458 - 1.462 - 9 - 231447 Suitable absorption enhancing system components for use in this invention which are commercially available are LABRASOL. produced by Gattefosse Corporation, Paris, France (PEG-8 caprylate/caprate glyceride esters), and SOFT1GEN 767. produced by Dynamit Nobel, West Germany (PEG-6 caprylate/caprate glyceride esters). The C, to C carboxylic acid or its salt which o lo constitutes absorption enhancing system component (b)(2)(ii) is derived from an acyclic carboxylic acid, which may be straight or branched chain. Examples include caproic, caprylic. capric. lauric. myristic, oleic, palmitic and stearic. Most favored for the purposes of this invention are caprylic and capric acids. These salts can be prepared in a conventional manner and using known techniques by reacting the acid with a base having a non-toxic, pharmacologically and pharmaceutically acceptable cation. In general, any base which will form a salt with a carboxylic acid and the pharmacological properties of which will not cause an adverse physiological effect when ingested by or otherwise administered to a warm-blooded animal is suitable. Such bases thus include, for example, alkali metal and alkaline earth metal hydroxides or carbonates, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, and the like. Particularly preferred for this invention are sodium salts, chiefly because of their ready availability. Absorption enhancing system component (b)(2)(iii) is derived from a mixture of two or more carboxylic acids of 6 to 18 carbon atoms, glycerol and a polyoxyethylene glycol. The acids may be straight or branched chain, and saturated or unsaturated. Suitable acids include saturated carboxylic acids such as n-hexyl, n-heptyl, n-octyl, n-decyl, lauryl, myristyl. 23144 cetyl and n-octadecyl, and unsaturated enoic (e.g., oleic) and dienoic (e.g., linoleic) acids. Preferred are mixtures comprised of several C, to o C^8 fatty acids, such as found in vegetable oils and fats, and most preferably coconut oil, which is composed of major amounts of saturated and minor amounts of unsaturated fatty acids of up to 18 carbon atoms. Preferably, the polyoxyethylene glycol employed for absorption enhancing system component (b)(2)(iii) is characterized by a number average molecular weight in the range from about 200 to about 1500, and more usually from about 300 to about 600. Absorption enhancing agents useful as absorption enhancing system component (b)(2)(iii) can be prepared by those skilled in the art using conventional esterification procedures. A suitable material is available commercially from Capital City Products, Janesville, Wisconsin under the trade designation ACCONON CON (a PEG glycerol cocoate). The relative proportions of the two components which comprise the absorption enhancing system can be varied to achieve optimum results for a particular embodiment of the invention. Preferably, the weight ratio of (b)(1) to (b)(2)(i), (b)(2)(ii) or (b)(2)(iii) is in the range from about 1:50 to about 50:1. more preferably from about 1:10 to about 10:1. and most preferably from about 1:4 to about 4:1. The effective amount of the absorption enhancing system, component (b). in the composition of this invention will vary depending on such factors as the particular antibacterial compound being employed and its amount, as well as the age of the subject being treated. In general, for oral dosage form compositions of this 231447 invention, it is preferred to employ from about 50 to about 1000 milligrams (mg), and more preferably from about 100 to about 500 mg of the absorption enhancing system, for each unit dose of the composition. These compositions will usually contain the antibacterial compound in amounts from about 10 to about 500 mg, and more usually from about 50 to about 250 mg, per unit dose. Rectal dosage form compositions in accordance with this invention will usually contain from about 50 to about 1500 mg, more preferably from about 75 to about 600 mg of the absorption enhancing system, for each unit dose of the composition. Such compositions will usually contain the antibacterial compound in amounts from about 10 to about 3000 mg, and more usually from about 100 to about 1500 mg, per unit dose. The term "unit dose" is used here in the conventional sense to mean a single application or administration of the drug to the subject being treated in an amount as stated above, but it should be understood that the amount can be given in the form of a single pill, tablet, capsule, suppository, etc., or alternatively, in multiples of two or more of such dosage units with the total adding up to the stated amount of drug. The described antibacterial compound and absorption enhancing system, components (a) and (b), respectively, can be incorporated into a vehicle, if desired. As the vehicle, there can be used any pharmaceutically acceptable solid, semi-solid or liquid carrier in which these components are soluble or readily dispersible. Some examples include but are not limited to cocoa butter, polyethylene glycols, polypropylene glycols, methylcellulose, carboxymethyl- © cellulose and Suppocire semi-synthetic bases (Gattefosse Corp., Paris, France). Preferably, the vehicle is a solid. Favored as a solid vehicle for the compositions - 12 - 2314 47 of this invention are mixtures of mono-, di- and triglycerides of C to C natural saturated fatty 1Z 18 acids, preferably vegetable fatty acids having an even number of carbon atoms (Cn_, C,., C,, etc.)- 1Z 14 lb Especially suitable and preferred are the pharmaceutical bases of Dynamit Nobel having the trade designation "WITEPSOL". Still other pharmaceutically compatible carrier materials may be employed as desired and depending upon particular requirements, the selection of which is within the knowledge of those skilled in the art. If utilized, the vehicle will generally be present in those amounts which are conventional for pharmaceutical carrier materials and which can be reasonably and safely administered. The preferred method of orally administering the combination of antibacterial compound and absorption enhancing system in accordance with this invention is in the form of an enteric coated entity, and more specifically, an enteric coated solid dosage form. The formulation can be filled into a hard- or soft-shell capsule or, if the formulation is a liquid, absorbed onto a suitable carrier to make a free flowing powder and then filled into the capsule or, alternatively, compressed into a pill or tablet. Still other possible dosage forms include microcapsule or beadlet forms of the antibacterial compound mixed with the absorption enhancing system which may thereafter be encapsulated in an enteric coated capsule. Usage of enteric coating materials in this manner serves to protect the antibacterial compound from the gastric fluid and to achieve optimum delivery of the antibacterial compound together with the absorption enhancing system to the intestine. The enteric coating material is, for the - 13 - 231447 most part, resistant to the gastric fluid and is unaffected by it but dissolves in the intestinal fluid to cause release of the drug. The effectiveness of particular enteric coating materials can be measured using known USP procedures. By way of illustration, suitable enteric coating materials for purposes of this invention include but are not limited to the following: cellulose acetate phthalate cellulose acetate trimellitate hydroxypropyl methylcellulose phthalate hydroxypropyl methylcellulose phthalate succinate polyvinyl acetate phthalate methacrylic acid methacrylic acid esters These enteric coating materials may be applied with or without plasticizers. such as acetylated glycerides or diethylphthalate. using methods known to those skilled in the art. The percentage of enteric coating applied is usually between about 1 and about 10 percent by weight, or more, and most desirably from about 2 to about 8 percent by weight, based on the total weight of the unit dosage form, i.e., the total capsule or tablet weight. Examples of suitable enteric coating formulations are given below. - 14 - 231447 Enteric Coating Formulations 5 ingredients % w/w Preparation A: 10 Hydroxypropyl methylcellulose phthalate (HPMCP) 5.0 Triacetin 0.5 Methylene chloride 47.25 Denatured alcohol 47.25 15 Preparation B: 20 HPMCP Titanium dioxide Dimethyl polysiloxane Acetone Denatured alcohol 10.0 0.2 0.05 44 .875 44 .875 Preparation C: 25 Cellulose acetate phthalate (CAP) Diethyl phthalate Titanium dioxide Acetone Denatured alcohol 30 8.5 1-5 0.2 44 . 9 44 .9 Preparation D: Polyvinyl acetate phthalate Acetylated glycerides 35 Methylene chloride Denatured alcohol 5.0 0.8 47.1 47.1 2314 47 - 15 - 5 -s .y 10 15 20 25 V 30 35 Preparation E: Methacrylic acid or methacrylic acid ester (Eudragit S or L. 8.0 Rohm Pharma, GMBH, Wetterstadt, West Germany) Acetone 46.0 Anhydrous alcohol 46.0 Plasticizer q.s. Oral dosage form compositions in accordance with this invention can also be formulated to additionally contain conventional additives or supplementary ingredients, in the usual amounts for such materials. By way of illustration, such additives or supplements include thickening agents, such as silicic acid (for instance, the trade designated "Aerosil" products); bentonites; colloidal clay; carboxymethyl celluloses; modified montmorillonites, such as alkyl ammonium salts of montmorillonites (for instance, the commercial products known as "Bentone"); organic thickening and structure-forming agents, such as saturated higher fatty acids and alcohols containing from 12 to 20 carbon atoms (for instance, stearic or palmitic acids, or stearic or cetyl alcohols); waxes; monoglycerides of saturated or unsaturated high fatty acids such as stearic acid, palmitic acid or oleic acid; gelling agents, such as aluminum stearate; dispersing agents, such as ionic, non-ionic or cationic surfactants; emulsifying agents, such as lecithin, and so forth. The compositions of this invention can also contain pharmaceutically acceptable adjuvants, such as binders or lubricants for tabletting, stabilizing agents, antioxidants, flowing agents (to enhance pourability or flowability during processing), preservatives, flavoring agents, coloring agents and buffering agents. Any of these can be selected from among materials known for such purposes and used in 231 44 conventional amounts. In vivo tests were utilized to evaluate the enhanced mucosal tissue absorption of antibiotics administered in accordance with this invention. IN VIVO (RATS) - ENTERAL Adult Sprague-Dawley female rats (Charles River Breeding Laboratories, Kingston, New York), weighing about 250 grams each, were fasted overnight and anesthetized with metofane. With each rat, an incision was made on the ventral surface to expose the intestine. Administration of an antibiotic was carried out using a solution dosage form. The solutions were prepared by dissolving 5 mg of antibiotic in water with or without absorption enhancer and diluting to the desired concentration. Each solution of antibiotic in water was administered enterally by injecting with a syringe into the duodenum below the pyloric valve. For purposes of comparison, the solution was alternatively administered intravenously by injecting with a syringe into a tail vein. Plasma Levels of Antibiotic in Rats The concentration of antibiotic in rat plasma was determined at various time intervals after intravenous or enteral administration. Blood samples were collected from the tail of each test animal prior to administration of the antibiotic and at 5, 10, 20, 40, 60, 120, 240 and 360 minutes after administration, then centrifuged at 3200 rpm for 5 to 10 minutes, after which the plasma was withdrawn and frozen until assayed. - 17 - 231447 Bioassay of Plasma Samples Most of the antibiotics tested had exhibited some degree of protein binding when drug-spiked rat plasma was assayed 5 against drug in H20. Any antibiotic not bound by plasma was diluted in B.^0 and assayed against standards prepared in H^O. For bound antibiotics, the influence of protein binding was negated by diluting all standards and samples in pooled rat plasma. In the case of ceftriaxone and 10 cefazolin, the effect of binding was accounted for by deproteinizing plasma samples with acetonitrile with a dilution factor of 1:12 and assaying against a standard curve diluted in H20. Antibiotic levels were assayed on nunc plates employing the appropriate agar seeded with 15 bacteria, as listed below. 20 25 30 35 - 18 - 231447 Antibiotic Assay Oroanism Range or Standard Curves (rocq/ml) Bioassay Volume Media (mcl) 10 15 20 Carunonam Ampicillin1 Cefamandole . 1 Cefotaxime . . 1 Cefoxitin E. coli. 1346 32-1 2 AA#1 20 M. lutea ATCC 9341 8-0.25 AA#1 20 M. lutea ATCC 9341 32-1 AA#1 20 E. coli. 1346 8-0.25 or 16-0.5 AA#1 20 S. aureus MB2786 64-4 3 BHI 20 Ceftriaxone1 Cefazolin1 E. coli. 1346 4-0.125 AA#1 20 S. aureus ATCC 25923 32-1 AA#1 50 Noxalactam^ Penicillin G1 B. subtil is spores 32-2 AA#1 50 E. coli. 1346 50-1.56 AA#1 50 M. lutea ATCC 9341 8-0.5 AA#1 20 Mezlocillin1 . . 1 Gentamicin . 1 Vancomycin K. lutea ATCC 9341 16-1 AA#1 50 K. pneumoniae A 80-2.5 4 MH 50 B. cereus ATCC 11778 64-2 AA#85 50 1 25 5 Antibiotics protein bound in rat plasma. 2 AA#1 = antibiotic agar #1 (Difco). 3 BHI = Brain Heart Infusion Media (Difco). 4 1*4 = Mueller Hinton Agar (Difco). AA#8 = antibiotic agar #Q (Difco). mcg/ml = micrograms per milliliter mcl = microliters 30 35 The plates were incubated overnight at 37 C and the zones of inhibition were read to the nearest 0.1 mm. Calculations were made using an autoassay machine (Giles Scientific. Inc., New York). For reference, see J. V. Bennett et al.. Applied Microbiology 14., 170-177 (1966). The results were as follows: 23 1 4 4 TABLE 1 10 Antibiotic ENTERAL ABSORPTION IN RATS -With and Without Absorption Enhancers Dose = 5 mq/0.5 ml Cmax (micrograms per milliliter) (Control) Acconon Con Labrasol Mater Laureth-12* Laureth-12* Sodium Caprylate (301) Laureth-12* Carumonam 0.0 ± 0.0 7.2 ± 1.4 11.7 ± 3.8 6.3 2.4 Cefamandole 1.3 + 2.5 6.4 ± 0.6 8.4 ± 2.6 18.1 + 3.7 Cefazolin 0.0 ± 0.0 42.9 ± 3.0 62.2 + 25.2 40.7 + 7.2 Cefoxitin 0.0 ± 0.0 7.7 ± 2.8 9.1 + 3.4 16.2 + 4.6 Cefotetan 0.0 ± 0.0 9.5 ± 2.8 21.2 ± 5.8 26.1 ± 11.4 Gentamicin 3.9 15.4 ± 2.3 9.6 ± 1.9 14.1 ± 6.9 Mezlocillin 0.0 ± 0.0 0.6 ± 1.0 1.4 ± 1.4 6.7 + 1.7 Moxalactam 0.0 ± 0.0 9.6 ± 2.2 16.2 ± 1.8 19.9 + 4.5 Penicillin G 0.5 ± 0.1 3.5 ± 1.0 5.2 ± 1.6 7.4 + 2.4 Vancomycin 2.9 ± 0.6 0.0 ± 0.0 6.9 ± 1.0 9.8 ± 3.5 Ceftriaxone 2.4 ± 1.9 38.8 ± 22.6 105.5 ± 23.0 53.7 ± 13.3 ♦Weight Ratio of Other Absorption Enhancer Conponent to Laureth-12 was 8:1 30 35 - 20 - 231447 IN VIVO (DOGS) - ENTERAL Six male beagle dogs, weighing about 10 to 16 kilograms each, were chronically fitted with a modified Thomas cannula 5 implanted in the distal duodenum. Each dog received 2 hard shell gelatin capsules containing 210 mg of ceftriaxone sodium salt in 280 mg of a base (WITEPSOL H15), with absorption enhancer (157.5 mg of Labrasol and 52.5 mg of —■ Laureth-12). Administration of the capsules in each -to instance was enteral through the modified Thomas cannula into the proximal jejunum. Drug dosage was 20 to 50 mg of ceftriaxone per kilogram of dog body weight. Blood plasma concentrations of ceftriaxone were -15 determined prior to administration and at 10, 20, 40, 60, 120, 180 and 240 minutes after administration. Measurements were made by withdrawing blood at these time intervals, centrifuging, separating the plasma and assaying by High Performance Liquid Chromatography (HPLC), reverse phase 20 method, or by bioassay (the same procedure as previously described for the Bioassay of Plasma Samples). To establish a standard curve, ceftriaxone was diluted with normal dog plasma, then deproteinized in the same 25 manner as described previously. Calculations were conducted using a Waters 840 Computer System. Through the use of an appropriate computer program, the area under the curve (AUC) ^ was determined for each route of administration. From these determinations, the bioavailability was computed using the 30 following equation: . rAUC Enterall % Bioavailability = [AUC IV] x 35 Whenever intravenous (I.V.) data were not available for the same dose level used enterally, the following equation was employed: - 21 - 231447 fAUC Enteral 1 n.v. Dosel % Bioavailability = [auc j.v.j * [Enteral Dose] x 100 The results were 45.4 ± 18.2% Bioavailability and 19.5 ± 6.5 mcg/ml Cmax for the absorption enhanced formulation, compared to 0% Bioavailability and 0.5 mcg/ml Cmax for the control (a solution of ceftriaxone in water equivalent to 25 mg/kg, no absorption enhancers). IN VIVO (BABOONS) - ORAL Adult baboons (papio anubis and Papio hamadryas). ranging in weight from 12 to 30 kilograms, were used in this study. The baboons were fasted overnight, then sedated with ketamine hydrochloride by intramuscular injection prior to administration of the antibiotic. Each baboon received four hard shell gelatin capsules through a gastric tube. Each capsule contained the following: Ceftriaxone sodium salt 300 mg Labrasol 225 mg Laureth-12 75 mg Witepsol HI5 380 mg 9 80 mg Enteric coating: polyvinyl acetate phthalate (approximately 8% of total capsule weight) One-milliliter blood samples were taken from the femoral region of each baboon using a heparinized 3-ml syringe. Samples were taken prior to ceftriaxone administration and at 15, 30, 60, 120. 240, 360, 480. 600 and 720 minutes following ceftriaxone administration. The samples were centrifuged at 12,000 rpm for one minute and the plasma was separated and bioassayed for antibiotic content after deproteinization with acetonitrile, using the same procedure described previously for the Bioassay of Plasma Samples. - 22 - 231447 The results were 10.0 ± 6.5% Bioavailability and 5.5-59.8 mcg/ml Cmax range, compared to 0% Bioavailability and 0 mcg/ml Cmax for the control (ceftriaxone sodium salt, 300 mg, in the same enteric coated capsule, no absorption 5 enhancers). Absorption was also evaluated using a formulation composed of 300 mg of ceftriaxone sodium salt, 200 mg of sodium caprylate. 75 mg of Laureth-12 and 415 mg of Witepsol 10 H15. The Bioavailability of this formulation was 15.7 ± 9.9% and 15.0-66.3 mcg/ml Cmax range, compared to 0% Bioavailability and 0 mcg/ml Cmax for the control (same as above). 15 IN VIVO (DOGS) - ORAL Male beagle dogs weighing approximately 10-14 kilograms were used in this study. The dogs received 2 or 3 hard shell capsules through a gastric tube. Each capsule 20 contained the following: Ceftriaxone sodium salt 300 mg 'O Labrasol 225 mg Laureth-12 75 mg 25 Witepsol H15 380 mg 980 mg Enteric coating: polyvinyl acetate phthalate (approximately 8% of total capsule weight) 30 Blood plasma concentrations of ceftriaxone were determined prior to administration and at 10, 20, 40, 60, 120, 180 and 240 minutes after administration. Measurements were made by withdrawing blood at these time intervals, 35 separating the plasma, deproteinizing, and assaying by High Performance Liquid Chromatography (HPLC), reverse phase method, or by the previously described Bioassay of Plasma - 23 - 231447 Samples method. The results were 34.2 ± 14.0% Bioavailability and 21.6 ±7.6 mcg/ml Cmax for the above formulation, and 0% 5 Bioavailability and 0 mcg/ml Cmax for the control (ceftriaxone sodium salt, 300 mg, in the same enteric coated capsule, no absorption enhancers). Absorption was also evaluated using a formulation 10 composed of 300 mg of ceftriaxone sodium salt, 200 mg of sodium caprylate, 75 mg of Laureth-12 and 415 mg of Witepsol H15. Bioavailability was 22.4 ± 13.5% and Cmax was 14.4 ± 8.4 mcg/ml, compared to 0% and 0 mcg/ml, respectively, for the control (same as above). 15 IN VIVO (BABOONS) - RECTAL Male and female adult baboons (Papio anubis and Papio hamadryas). ranging in weight from 12 to 27 kilograms, were 20 used in this study. The baboons were fasted for 24 hours prior to administration of antibiotic, then sedated with ketamine hydrochloride by intramuscular injection prior to •. / administration of the antibiotic. Suppositories made up of the formulations shown below were administered to the 25 baboons and the rectal openings were then taped closed to prevent expulsion and leakage of the suppository mass. Antibiotic 500 mg Laureth-12 125 mg 30 Labrasol 250 mg Witepsol H15 1125 mg Total: 2000 mg 35 To measure antibiotic absorption into the bloodstream, blood samples were taken from the femoral region of each baboon, using heparinized 3-ml syringes, prior to antibiotic 231447 administration and at 15, 30, 60, 120, 240, 360 and 480 minutes after antibiotic administration. The withdrawn samples were centrifuged at 12,000 rpm for one minute and bioassayed by the previously described Bioassay of Plasma 5 Samples method. The results were as follows: TABLE 2 Antibiotic Bioavailability and Cmax Range in Baboons After Rectal Administration Antibiotic Ceftriaxone Cefamandole Cefoxitin Penicillin G With Absorption Enhancer System % Bioavail- Cmax Range ability ' mcg/ml 31.5 ± 13.1 46.5 ± 16.6 77.0 ± 22.5 38.2 ± 26.1 18.2-49.6 5.9-16.4 4.7-10.8 2.0-11.1 Control-No Absorption Enhancer System % Bioavail- Cmax Rang ability mcg/ml 4.3 ± 2.8 6.0 ± 2.3 O 17.4 i 8.0 0.3-9.0 2.3-4.6 0 1.2-2.4 Absorption was also evaluated using a formulation composed of 600 mg of ceftriaxone sodium salt, 200 mg of sodium caprylate, 125 mg of Laureth-12 and 1075 mg of 25 Witepsol Hl5 (total: 2000 mg). The Bioavailability was 49.3 ± 13.7% and the Cmax range was 68.1-102.8 mcg/ml, compared to 4.3% Bioavailability and 0.3-9.0 mcg/ml Cmax range for the control (600 mg of ceftriaxone sodium salt in suppository vehicle with no absorption enhancers). 30 By way of illustration, some suitable formulations for various dosage forms in accordance with this invention are set forth below. While ceftriaxone, the preferred antibiotic for this invention, is used to illustrate these 35 formulations, it should be understood that other antibiotics may be substituted in appropriate amounts. 231447 ORAL DOSAGE FORMS per capsule Ceftriaxone (sodium) 60 mg 120 mg 210 mg 300 mg Labrasol 225 mg 225 mg 225 mg 225 mg Laureth-12 75 mg 75 mg 75 mg 75 mg Witepsol H15 340 mg 340 mg 340 mg 340 mg Ceftriaxone (sodium) 60 mg 120 mg 210 mg 300 mg Sodium caprylate 200 mg 200 mg 200 mg 200 mg Laureth-12 75 mg 75 mg 75 mg 75 mg Witepsol H15 365 mg 365 mg 365 mg 365 mg Ceftriaxone (sodium) 60 mg 120 mg 210 mg 300 mg Acconon Con 225 mg 225 mg 225 mg 225 mg Laureth-12 75 mg 75 mg 75 mg 75 mg witepsol H15 340 mg 340 mg 340 mg 340 mg Ceftriaxone (sodium) 60 mg 120 mg 210 mg 300 mg Softigen 767 225 mg 225 mg 225 mg 225 mg Laureth-12 75 mg 75 mg 75 mg 75 mg Witepsol H15 340 mg 340 mg 340 rag 340 mg RECTAL DOSAGE FORMS per suppository Ceftriaxone (sodium)180 mg 300 mg 600 mg 1200 mg Labrasol 250 mg 250 mg 250 mg 500 mg Laureth-12 125 mg 125 mg 125 mg 250 mg Witepsol H15 1445 mg 1325 mg 1025 mg 2050 mg Ceftriaxone (sodium)180 mg 300 mg 600 mg 1200 mg Sodium caprylate 200 mg 200 mg 200 mg 400 mg Laureth-12 125 mg 125 mg 125 mg 250 mg Witepsol H15 1495 mg 1375 mg 1075 mg 2150 mg </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 10 - 26 23 14 4" C) Ceftriaxone (sodium)180 mg 300 mg 600 mg 1200 mg Acconon Con 250 mg 250 mg 250 mg 500 mg Laureth-12 125 mg 125 mg 125 mg 250 mg Witepsol H15 1445 mg 1325 mg 1025 mg 2050 mg D) Ceftriaxone (sodium)180 mg 300 mg 600 mg 1200 mg Softigen 767 250 mg 250 mg 250 mg 500 mg Laureth-12 125 mg 125 mg 125 mg 250 mg Witepsol H15 1445 mg 1325 mg 1025 mg 2050 mg The above dosage forms can be prepared as follows: PROCEDURES 15 Oral 20 25 The base (Witepsol H15) is warmed to 55°C and the absorption enhancer system components are added to the melt with mixing. The melt is then cooled to 45°C and the drug (ceftriaxone sodium) is added to the molten mass and mixed until uniformly distributed and free of any aggregates. The mass is homogenized, if necessary, to obtain a uniform suspension. The suspension is filled into gelatin capsules, sealed if necessary, and the capsules are enteric coated. Rectal The base (Witepsol H15) is warmed to 55°C and the absorption enhancer system components are added to the melt 30 with mixing. The melt is then cooled to 45°C and the drug (ceftriaxone sodium) is added to the molten mass and mixed until uniformly distributed and free of any aggregates. The mass is homogenized, if necessary, to obtain a uniform suspension. The suspension is then filled into suppository 35 shells and allowed to cool and congeal. - 27 - 231447 WHAT WE CLAIM IS:

1. A pharmaceutical composition comprising (a) an antibacterial compound and (b) an absorption enhancing amount of a two-component absorption enhancing system made up of a first component which is (1) an ether of a Cg to Q. 0 alcohol and a polyoxyethylene glycol having an average 1 O molecular weight of from 40 0 to 600 and a second component selected from among (2)(i) a polyoxyethylene glycol (PEG)-Cg to C^g carboxylic acid glyceride ester, (2)(ii) a Cg to C carboxylic acid or pharmaceutically acceptable salt 18 thereof, and (2)(iii) an ester of two or more c, to C 6 18 carboxylic acids, glycerol and a polyoxyethylene glycol, with or without (c) a pharmaceutically inert carrier.

2. A composition according to claim 1. in which the absorption enhancing system is composed of (b)(1) an ether of a C. to C alcohol and a polyoxyethylene glycol having D 18 an average molecular weight of from 400 to 600 and (b)(2)(i) a polyoxyethylene glycol- Cg to Clg carboxylic acid glyceride ester.

3. A composition according to claim 2, in which (b)(1) is an ether of lauryl alcohol and polyoxyethylene glycol with 12 oxyethylene units and (b)(2)(i) is a PEG-8 caprylate/caprate glyceride ester.

4. A composition according to claim 1, in which the absorption enhancing system is composed of (b)(1) an ether of a C6 to Clg alcohol and a polyoxyethylene glycol having an average molecular weight of from 400 to 600 and (b)(2)(ii) a C, to C.. carboxylic acid or pharmaceutically o 18 acceptable salt thereof. an ether of lauryl alcohol and polyoxyethylene gl^

5. A composition according to claim 4. in which < with 12 oxyethylene units and (b)(2)(ii) is sodium caprylate. \ N- lir^ - 28 -

6. A composition according to claim 1, in which the absorption enhancing system is composed of (b)(1) an ether of a C6 to C18 alcohol and a polyoxyethylene glycol having an average molecular weight of from 400 to 6 00 and (b)(2)(iii) an ester of two or more C. to C, carboxylic b lo acids, glycerol and a polyoxyethylene glycol.

7. A composition according to claim 6. in which (b)(1) is an ether of lauryl alcohol and polyoxyethylene glycol with 12 oxyethylene units and (b) (2)(iii) is a PEG glycerol cocoate.

8. A composition according to any one of claims 1-7, in which the antibacterial compound is a beta-lactam.

9. A composition according to claim 8, in which the beta-lactam is of the formula «3V .Ri in which R1 is hydrogen or optionally substituted alkyl, R is SO -M+ where M+ is a proton or cation, R is an acylamino group or hydroxyalkyl. or R^ and R2 together with the beta-lactam (azetidinone) ring to which they are bonded represent *3, in which X is -S-. -O-, -SOT -SO-CH~ or -CH(CH3)-and Y is group COOE in which R^ is a substituted thio group selected from among ethylthio, -SCH2CH2NH2, NH o II II /-v -SCH2CH2NHCH, -SCH2CH2OCNH2. -S—< }—CONMe2 '—NH 20 or an optionally substituted lower alkyl group selected from among aminomethyl, acylaminomethyl, "KJ or or a substituted oxy group consisting of carbamoyloxy 25 O u (-OCNH2), and the carbon atom which carries the -COOE group is bonded to the nitrogen atom of the beta-lactam ring, Z is hydrogen, halogen, alkoxy or CH2T, with T denoting hydrogen, alkyl -CO-O-, pyridinium, 30 carboxamidopyridinium, aminopyridinium, carbamoyloxy, azido, cyano, hydroxyl, the group -S-phenyl which can be substituted or the group -S-het wherein "het" is an optionally substituted 5- or 6-membered heterocyclic ring, and E is hydrogen, a pharmaceutically acceptable ester group 35 or a salt-forming cation. Pi 231447 - 30 -

10. A composition according to claim 8 in which, the beta-lactam is (E)-2-(Isobutoxy carbonyl) -2-pentenyl(6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl) -2-(methoxyiminoJacetamido]-3-(azidomethyl)-8-0X0-5-thia 5 -l-azabicyclo[4.2.0]oct-2-ene-2-carboxylate.

11. A composition according to claim 8, in which the beta-lactam is ceftriaxone or a pharmaceutically acceptable salt, ester or hydrate thereof. 10

12. A composition according to any one of claims 1-11, which is in an enteric coated oral dosage form.

13. A composition according to any one of claims 1-11, which is in a rectal dosage form.

14. A composition according to claim 1 and substantially as hereinbefore described. 20 ')aied day of 19c\3l A. J. PARK & SON fza agents for the applicants 25 15 30 i \0 \ - </div>